Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033135549> ?p ?o ?g. }
- W3033135549 abstract "Abstract Background and Aims Chronic kidney disease (CKD) is a major public health issue worldwide including in China. One of the most common complication in advanced Chronic kidney disease (CKD) is secondary hyperparathyroidism (SHPT). Reports show higher risk of bone fracture, cardiovascular events and all-cause mortality is associated with uncontrolled SHPT in patients with CKD. Cinacalcet, a calcimimetic agent was reported to reduce iPTH levels without Ca increase in patients with SHPT previously. However there has been no large-cohort study and stratified analysis of cinacalcet based on the level of iPTH in China. Moreover, the optimal therapeutic doses of cinacalcet with mild-to-severe SHPT is remaining unknown. ACTIVE study is an IV, open-label, multicenter clinical trial aimed to: (1) evaluate the efficacy and safety of cinacalcet in maintenance hemodialysis patients with mild-to-severe SHPT; (2) explore optimal combinations therapy with cinacalcet and other agents for treating patients with CKD-mineral and bone disorder. (3) investigate the benefit of long-term, continuous medication with cinacalcet in the real-world setting. Method The study design was reported on 2019 ASN. Key inclusion criteria were a baseline iPTH ≥300 pg/mL with life expectancy of ≥2 years, and ≥12 weeks of maintenance dialysis (three dialysis sessions per week) prior to enrollment. The enrollments were grouped based on their iPTH level as having mild (300-600 pg/mL), moderate (600-900 pg/mL) or severe (≥900 pg/mL). Patients initiated treatment with cinacalcet orally at a starting dose of 25 mg once daily (qd). The primary efficacy endpoint is the proportion of patients achieving iPTH targets (iPTH between 150-300pg/mL) at 20 and 32 weeks after the initiation of cinacalcet treatment. Adverse events and serious adverse events were recorded. An interim analysis was scheduled as 375 patients completed 32 weeks visit. Results 911 patients were recruited and of 750 eligible patients, 275 were identified as mild, 224 were considered as moderate and left 251 were grouped as severe SHPT. The study flowchart of 375 patients including mild(127), moderate(106) and severe(142) SHPT for interim analysis was shown in Fig 1. The baseline results including demographic and biomarkers level were reported on 2019 ASN. After 4 weeks’ cinacalcet treatment, serum PTH decreased in all three group, while extremely remarkable in the severe SHPT group. Interim analysis results revealed that the proportion of patients achieving iPTH target (150-300 pg/mL) at 20 wk visit among mild, moderate and severe groups were 38.61% (39/101), 30.11% (28/93) and 10.91% (12/110) respectively. The proportion of patients achieving iPTH target at 32 wk visit in 3 groups increased to 44.68% (42/94), 27.27% (24/88) and 14.56% (15/103) respectively (Table.1). The trends of the proportion of patients achieving iPTH target increased in all 3 different groups (Fig.2). The safety analysis showed the most common treatment-related AE in top 3 including hypocalcemia, hyperlipidemia, and loss of appetite. In vital signs, electrocardiogram (ECG) and laboratory examination of descriptive analysis, found no obvious safety tips. This study is sponsored by Kyowa Hakko Kirin (China) Pharmaceutical Co., Ltd. The analysis is still ongoing and results will be released at EDTA meeting this year. Conclusion Oral cinacalcet HCl was effective and safe in reducing iPTH in patients receiving HD with mild-to-severe SHPT." @default.
- W3033135549 created "2020-06-12" @default.
- W3033135549 creator A5002902707 @default.
- W3033135549 creator A5004074649 @default.
- W3033135549 creator A5005988997 @default.
- W3033135549 creator A5007054845 @default.
- W3033135549 creator A5010836532 @default.
- W3033135549 creator A5015101913 @default.
- W3033135549 creator A5015482650 @default.
- W3033135549 creator A5016270123 @default.
- W3033135549 creator A5023236133 @default.
- W3033135549 creator A5023563380 @default.
- W3033135549 creator A5028277558 @default.
- W3033135549 creator A5037338561 @default.
- W3033135549 creator A5048379858 @default.
- W3033135549 creator A5055356572 @default.
- W3033135549 creator A5060354484 @default.
- W3033135549 creator A5060883903 @default.
- W3033135549 creator A5064478014 @default.
- W3033135549 creator A5066593507 @default.
- W3033135549 creator A5070172671 @default.
- W3033135549 creator A5070792980 @default.
- W3033135549 creator A5075015867 @default.
- W3033135549 creator A5077679832 @default.
- W3033135549 creator A5078586828 @default.
- W3033135549 creator A5080744317 @default.
- W3033135549 creator A5089972275 @default.
- W3033135549 date "2020-06-01" @default.
- W3033135549 modified "2023-09-26" @default.
- W3033135549 title "P0890EFFICACY AND SAFETY OF CINACALCET IN CHINESE MAINTENANCE HEMODIALYSIS PATIENTS WITH DIFFERENT STAGES OF SECONDARY HYPERPARATHYROIDISM: INTERIM ANALYSIS RESULTS OF ACTIVE STUDY" @default.
- W3033135549 doi "https://doi.org/10.1093/ndt/gfaa142.p0890" @default.
- W3033135549 hasPublicationYear "2020" @default.
- W3033135549 type Work @default.
- W3033135549 sameAs 3033135549 @default.
- W3033135549 citedByCount "0" @default.
- W3033135549 crossrefType "journal-article" @default.
- W3033135549 hasAuthorship W3033135549A5002902707 @default.
- W3033135549 hasAuthorship W3033135549A5004074649 @default.
- W3033135549 hasAuthorship W3033135549A5005988997 @default.
- W3033135549 hasAuthorship W3033135549A5007054845 @default.
- W3033135549 hasAuthorship W3033135549A5010836532 @default.
- W3033135549 hasAuthorship W3033135549A5015101913 @default.
- W3033135549 hasAuthorship W3033135549A5015482650 @default.
- W3033135549 hasAuthorship W3033135549A5016270123 @default.
- W3033135549 hasAuthorship W3033135549A5023236133 @default.
- W3033135549 hasAuthorship W3033135549A5023563380 @default.
- W3033135549 hasAuthorship W3033135549A5028277558 @default.
- W3033135549 hasAuthorship W3033135549A5037338561 @default.
- W3033135549 hasAuthorship W3033135549A5048379858 @default.
- W3033135549 hasAuthorship W3033135549A5055356572 @default.
- W3033135549 hasAuthorship W3033135549A5060354484 @default.
- W3033135549 hasAuthorship W3033135549A5060883903 @default.
- W3033135549 hasAuthorship W3033135549A5064478014 @default.
- W3033135549 hasAuthorship W3033135549A5066593507 @default.
- W3033135549 hasAuthorship W3033135549A5070172671 @default.
- W3033135549 hasAuthorship W3033135549A5070792980 @default.
- W3033135549 hasAuthorship W3033135549A5075015867 @default.
- W3033135549 hasAuthorship W3033135549A5077679832 @default.
- W3033135549 hasAuthorship W3033135549A5078586828 @default.
- W3033135549 hasAuthorship W3033135549A5080744317 @default.
- W3033135549 hasAuthorship W3033135549A5089972275 @default.
- W3033135549 hasBestOaLocation W30331355491 @default.
- W3033135549 hasConcept C126322002 @default.
- W3033135549 hasConcept C126894567 @default.
- W3033135549 hasConcept C141071460 @default.
- W3033135549 hasConcept C2778063415 @default.
- W3033135549 hasConcept C2778653478 @default.
- W3033135549 hasConcept C2778838027 @default.
- W3033135549 hasConcept C2779978075 @default.
- W3033135549 hasConcept C2780280601 @default.
- W3033135549 hasConcept C2780534505 @default.
- W3033135549 hasConcept C2781208988 @default.
- W3033135549 hasConcept C519063684 @default.
- W3033135549 hasConcept C535046627 @default.
- W3033135549 hasConcept C61943457 @default.
- W3033135549 hasConcept C71924100 @default.
- W3033135549 hasConceptScore W3033135549C126322002 @default.
- W3033135549 hasConceptScore W3033135549C126894567 @default.
- W3033135549 hasConceptScore W3033135549C141071460 @default.
- W3033135549 hasConceptScore W3033135549C2778063415 @default.
- W3033135549 hasConceptScore W3033135549C2778653478 @default.
- W3033135549 hasConceptScore W3033135549C2778838027 @default.
- W3033135549 hasConceptScore W3033135549C2779978075 @default.
- W3033135549 hasConceptScore W3033135549C2780280601 @default.
- W3033135549 hasConceptScore W3033135549C2780534505 @default.
- W3033135549 hasConceptScore W3033135549C2781208988 @default.
- W3033135549 hasConceptScore W3033135549C519063684 @default.
- W3033135549 hasConceptScore W3033135549C535046627 @default.
- W3033135549 hasConceptScore W3033135549C61943457 @default.
- W3033135549 hasConceptScore W3033135549C71924100 @default.
- W3033135549 hasLocation W30331355491 @default.
- W3033135549 hasOpenAccess W3033135549 @default.
- W3033135549 hasPrimaryLocation W30331355491 @default.
- W3033135549 hasRelatedWork W10418522 @default.
- W3033135549 hasRelatedWork W10980105 @default.
- W3033135549 hasRelatedWork W15956177 @default.
- W3033135549 hasRelatedWork W17795215 @default.
- W3033135549 hasRelatedWork W18673860 @default.
- W3033135549 hasRelatedWork W2277958 @default.
- W3033135549 hasRelatedWork W2700549 @default.